Revision as of 13:02, 3 January 2007 editAgjchs (talk | contribs)104 edits added external link← Previous edit | Revision as of 14:03, 3 January 2007 edit undoJmax- (talk | contribs)910 editsm Reverted edits by Agjchs to last version by 216.153.202.18Next edit → | ||
Line 14: | Line 14: | ||
* | * | ||
* free PDF containing comprehensive charts | |||
] | ] |
Revision as of 14:03, 3 January 2007
Noradrenergic and specific serotonergic antidepressants (abbreviated: NaSSAs) are a relatively new class of antidepressants. They are thought to act by noradrenergic autoreceptor and heteroreceptor antagonism combined with specific serotonergic antagonism. This results in increases in both noradrenergic and specific serotonergic transmission.
Examples of NaSSAs include:
- Mirtazapine (Remeron®, Zispin®, Avanza®, Norset®, Remergil®)
NaSSAs are said to have fewer side effects than tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) while being equally effective. In particular, it is said that the sexual dysfunction that is a relatively common side effect of SSRIs occurs significantly less often during treatment with NaSSAs.
See also
External links
This medical treatment–related article is a stub. You can help Misplaced Pages by expanding it. |
..
Categories: